Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
Risk assessment update: seasonal influenza, EU/EEA, 2016–2017
This updated risk assessment provides an overview of the current influenza situation in Europe.
Risk assessment of seasonal influenza, EU/EEA, 2016/2017, 24 December 2016
Early-season risk assessment for EU/EEA countries to inform national public health authorities of the key attributes of the ongoing influenza season.
Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)
A consultation with European and international public health experts was convened to review data presented in newly conducted systematic reviews and meta-analyses regarding influenza antivirals, in order to develop an ECDC Expert Opinion.
Mid-season risk assessment: Seasonal influenza 2015–2016 in the EU/EEA countries
This risk assessment summarises the development of the 2015–16 influenza season, which so far has been characterised by a prevalence of type A viruses.
Rapid risk assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV). 19th update, 31 July 2015
This update was prompted in order to reassess the risk for European travellers to South Korea now that there have been no additional cases reported since 4 July 2015.
Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV), 5 June 2015
This risk assessment was triggered by a large cluster of confirmed MERS-CoV cases in South Korea, generated by a primary case imported from the Middle East. This is the largest cluster observed outside of the Arabian Peninsula so far.
Rapid Risk Assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV), 15th update, 9 March 2015
Since April 2012 and as of 7 March 2015, 1 082 cases (including 439 deaths) of Middle East respiratory syndrome coronavirus (MERS-CoV) have been reported by local health authorities worldwide.